C&Y Pharmaceutical(SZ:300254)2025-04-30 09:30Group 1: Financial Performance and Stock Management - The company has not considered stock buybacks or increases at this time, but will follow regulatory procedures if such plans arise [3] - The company acknowledges stock price fluctuations are influenced by various factors and aims to enhance operational performance to boost investor confidence [3] - The company reported a significant increase in revenue from its smoking cessation drug, with expectations for continued growth [4] Group 2: Product Development and Market Strategy - The company emphasizes the importance of research and development, with increasing investment in R&D over recent years [3] - New products are expected to be launched in the coming years, supported by funds raised through stock issuance in 2020 and 2021 [3] - The company plans to maintain a multi-channel marketing strategy to expand its market share and develop new business opportunities [4] Group 3: Cost Management and External Factors - To mitigate risks from raw material price fluctuations, the company will increase suppliers and improve production efficiency [2] - The impact of tariffs on the company's operations is minimal, as most business is domestic with only a small percentage of materials sourced from the U.S. [5] - The company does not anticipate new products entering the national procurement directory this year, as most of its main products are already included [5]